Don't Buy Qiagen Before Checking Its Fundamentals!

With gains of 2.8%, Qiagen was one of the winners on Wall Street today. Its shares are now trading at $46.18 and have logged a -1.0% daily outperformance of the S&P 500. Don't join the feeding frenzy before checking some basic facts about this stock:

  • Qiagen has moved -2.5% over the last year, and the S&P 500 logged a change of -1.4%

  • QGEN has an average analyst rating of buy and is -14.91% away from its mean target price of $54.27 per share

  • Its trailing earnings per share (EPS) is $1.85

  • Qiagen has a trailing 12 month Price to Earnings (P/E) ratio of 25.0 while the S&P 500 average is 15.97

  • Its forward earnings per share (EPS) is $2.32 and its forward P/E ratio is 19.9

  • The company has a Price to Book (P/B) ratio of 3.03 in contrast to the S&P 500's average ratio of 2.95

  • Qiagen is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16

  • QGEN has reported YOY quarterly earnings growth of -30.8% and gross profit margins of 0.7%

  • The company has a free cash flow of $447.79 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter

  • QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS